factor viia

Summary

Summary: Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.

Top Publications

  1. ncbi Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells
    Xiaofeng Jiang
    Sol Sherry Thrombosis Research Center, Temple University School of Medicine, 3400 North Broad Street Room 300 OMS, Philadelphia, PA 19140, USA
    Thromb Haemost 100:127-33. 2008
  2. pmc Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium
    Samit Ghosh
    Biomedical Research Division, The University of Texas Health Center at Tyler, Tyler, Texas 75708, USA
    J Biol Chem 282:11849-57. 2007
  3. pmc Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection
    Prosenjit Sen
    Center for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, TX, USA
    Blood 117:3199-208. 2011
  4. ncbi Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage
    Carl J Hauser
    Department of Surgery, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02216, USA
    J Trauma 69:489-500. 2010
  5. ncbi Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage
    Stephan A Mayer
    Department of Neurology, Columbia University College of Physicians and Surgeons, New York, USA
    N Engl J Med 358:2127-37. 2008
  6. ncbi Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface
    S Ghosh
    Biomedical Research Division, The University of Texas Health Center at Tyler, Tyler, TX 75708, USA
    J Thromb Haemost 5:336-46. 2007
  7. ncbi Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia
    M C Poon
    Departments of Medicine, Pediatrics, and Oncology, University of Calgary and Foothills Hospital, Calgary, Alberta, Canada
    Blood 94:3951-3. 1999
  8. ncbi Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Hospital Clinic and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Spain
    Hepatology 47:1604-14. 2008
  9. pmc Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications
    Veronica Yank
    Stanford University, Stanford, CA, USA
    Ann Intern Med 154:529-40. 2011
  10. pmc Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
    Aaron C Logan
    Stanford University School of Medicine, Stanford, CA, USA
    Ann Intern Med 154:516-22. 2011

Detail Information

Publications279 found, 100 shown here

  1. ncbi Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells
    Xiaofeng Jiang
    Sol Sherry Thrombosis Research Center, Temple University School of Medicine, 3400 North Broad Street Room 300 OMS, Philadelphia, PA 19140, USA
    Thromb Haemost 100:127-33. 2008
    ..Targeting the TF-mediated cell signaling pathway might represent a novel strategy for the treatment of breast cancer...
  2. pmc Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium
    Samit Ghosh
    Biomedical Research Division, The University of Texas Health Center at Tyler, Tyler, Texas 75708, USA
    J Biol Chem 282:11849-57. 2007
    Although factor VII/factor VIIa (FVII/FVIIa) is known to interact with many non-vascular cells, activated monocytes, and endothelial cells via its binding to tissue factor (TF), the interaction of FVII/FVIIa with unperturbed endothelium ..
  3. pmc Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection
    Prosenjit Sen
    Center for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, TX, USA
    Blood 117:3199-208. 2011
    Recent studies have shown that factor VIIa (FVIIa) binds to the endothelial cell protein C receptor (EPCR), a cellular receptor for protein C and activated protein C, but the physiologic significance of this interaction is unclear...
  4. ncbi Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage
    Carl J Hauser
    Department of Surgery, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02216, USA
    J Trauma 69:489-500. 2010
    Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes.
  5. ncbi Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage
    Stephan A Mayer
    Department of Neurology, Columbia University College of Physicians and Surgeons, New York, USA
    N Engl J Med 358:2127-37. 2008
    ..We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes...
  6. ncbi Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface
    S Ghosh
    Biomedical Research Division, The University of Texas Health Center at Tyler, Tyler, TX 75708, USA
    J Thromb Haemost 5:336-46. 2007
    Variants of recombinant factor VIIa (rFVIIa) with increased intrinsic activity have been developed to improve efficacy in the treatment of bleeding disorders in the future...
  7. ncbi Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia
    M C Poon
    Departments of Medicine, Pediatrics, and Oncology, University of Calgary and Foothills Hospital, Calgary, Alberta, Canada
    Blood 94:3951-3. 1999
    ..No adverse effects of rFVIIa were observed. Although the number of patients is small, our study suggests that rFVIIa may be an alternative to platelet transfusions in patients with a severe congenital thrombocytopathy...
  8. ncbi Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Hospital Clinic and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Spain
    Hepatology 47:1604-14. 2008
    ..A marked heterogeneity in the failure rate in all treatment groups was observed across participating centers. Adverse events, including overall thromboembolic events, were comparable between groups...
  9. pmc Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications
    Veronica Yank
    Stanford University, Stanford, CA, USA
    Ann Intern Med 154:529-40. 2011
    Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications.
  10. pmc Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
    Aaron C Logan
    Stanford University School of Medicine, Stanford, CA, USA
    Ann Intern Med 154:516-22. 2011
    Recombinant factor VIIa (rFVIIa) is approved for treatment of bleeding in patients who have hemophilia with inhibitors but has been applied to a wide range of off-label indications.
  11. ncbi Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand
    Vijender R Vaidyula
    Temple University Hospital, 3401 North Broad Street, Philadelphia, PA 19140, USA
    Diabetes 55:202-8. 2006
    ..2, factor VIII coagulant activity, and platelet CD40 ligand as well as decreases in factor VIIa, factor VII coagulant activities, and factor VII antigen...
  12. ncbi Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys
    Thomas W Geisbert
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
    Lancet 362:1953-8. 2003
    ..Here, we tested the notion that blockade of fVIIa/tissue factor is beneficial after infection with Ebola virus...
  13. ncbi Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism
    Todd A Hembrough
    EntreMed, Inc, Laboratory of Discovery Research, Rockville, Maryland 20850, USA
    Cancer Res 63:2997-3000. 2003
    ..coagulation on tumor growth, in vivo, we tested coagulation inhibitors specific for either tissue factor (TF)/factor VIIa (fVIIa) complexes or factor Xa (fXa) for antitumor activity...
  14. ncbi Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia
    J N Mahlangu
    Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital and University of Witwatersrand, Johannesburg, South Africa
    J Thromb Haemost 10:773-80. 2012
    BAY 86-6150 is a new human recombinant factor VIIa variant developed for high procoagulant activity and longer action in people with hemophilia with inhibitors.
  15. pmc Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
    R Gopalakrishnan
    Center for Biomedical Research, The University of Texas Health Science Center, Tyler, TX 75703, USA
    J Thromb Haemost 8:301-10. 2010
    Recent clinical studies suggest that the prophylactic use of recombinant factor VIIa (rFVIIa) markedly reduces the number of bleeding episodes in hemophilic patients with inhibitors...
  16. pmc Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis
    B M Mueller
    Department of Immunology, Scripps Research Institute, La Jolla, California 92037, USA
    J Clin Invest 101:1372-8. 1998
    ..Thus, extracellular functions of the catalytically active TF-VIIa complex cooperate with specific functions of the TF cytoplasmic domain to support the complex process of hematogenous tumor cell dissemination...
  17. ncbi Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors
    Lars C Petersen
    Haemostasis Biology, Health Care Discovery, Novo Nordisk, Maalov, Denmark
    Thromb Haemost 101:818-26. 2009
    ..All FVII derivatives studied including FVII, FVIIa and FVIIa-AT were cleared with similar rates suggesting an elimination kinetics which is unaffected by FVII activation and subsequent inactivation by plasma inhibitors...
  18. ncbi Raising the active site of factor VIIa above the membrane surface reduces its procoagulant activity but not factor VII autoactivation
    Emily K Waters
    Department of Biochemistry, College of Medicine, University of Illinois at Urbana Champaign, Urbana, Illinois 61801, USA
    J Biol Chem 281:26062-8. 2006
    ..trigger of blood clotting, is the membrane-anchored protein cofactor for the plasma serine protease, factor VIIa. Tissue factor is hypothesized to position and align the active site of factor VIIa relative to the membrane ..
  19. ncbi Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A
    Donald F Brophy
    School of Pharmacy, Coagulation Advancement Laboratory, Virginia Commonwealth University, Richmond, VA, USA
    Blood Coagul Fibrinolysis 21:539-46. 2010
    ..HAS and TEG assays provided similar estimates of FOT and R, however CEM appeared to be more sensitive than MA to changes in clot firmness...
  20. pmc Endothelial cell protein C receptor cellular localization and trafficking: potential functional implications
    Ramesh C Nayak
    Center for Biomedical Research, University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA
    Blood 114:1974-86. 2009
    ..A small fraction of EPCR is also localized intracellularly in the recycling compartment. Factor VIIa (FVIIa) or activated protein C binding to EPCR promoted the internalization of EPCR...
  21. ncbi Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial
    Erich V de Paula
    Hematology and Hemotherapy Center, University of Campinas, Sao Paulo, Brazil
    J Thromb Haemost 10:81-9. 2012
    A recombinant factor VIIa analog (NN1731; vatreptacog alfa [activated]) was developed to provide safe, rapid and sustained resolution of bleeds in patients with hemophilia and inhibitors.
  22. ncbi Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model
    Anne Godier
    Department of Anaesthesia and Critical Care, Paris Descartes University, Hotel Dieu University Hospital, Paris, France
    Anesthesiology 116:94-102. 2012
    ....
  23. ncbi Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells
    Xiaofeng Jiang
    Temple University School of Medicine, Sol Sherry Thrombosis Research Center, Philadelphia, PA 19140, USA
    Thromb Haemost 96:196-201. 2006
    Tissue factor (TF) is a transmembrane glycoprotein that initiates blood coagulation when complexed with factor VIIa (FVIIa)...
  24. ncbi The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry
    Peter Cameron
    Department of Epidemiology and Preventive Medicine, Monash University and Alfred Hospital Emergency and Trauma Centre, Melbourne, Australia
    Injury 38:1030-8. 2007
    ..The role of rFVIIa is not defined in this group of patients. Registries provide an opportunity to review the patients, reported response and adverse events for rFVIIa...
  25. ncbi Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity
    J López-Sagaseta
    Haematology Department and the Division of Cardiovascular Sciences, Laboratory of Thrombosis and Haemostasis, Clinica Universitaria School of Medicine, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain
    J Thromb Haemost 5:1817-24. 2007
    ..Factor VII (FVII), the coagulation trigger upon tissue factor (TF) interaction, is a serine protease whose Gla domain is highly homologous to the Gla domain of protein C...
  26. ncbi Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism
    Zhengwen Ma
    Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, China
    Int J Gynecol Cancer 21:616-24. 2011
    ..However, it is not clear how tumor-associated macrophage and TF-FVIIa complex promotes EOC invasion. In the present study, we aimed to determine the mechanism by which interaction of TF-FVIIa and monocytes (MOs) promotes EOC metastasis...
  27. ncbi Safety profile of recombinant factor VIIa
    Harold R Roberts
    Division of Hematology, Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill, USA
    Semin Hematol 41:101-8. 2004
    Recombinant factor VIIa (rFVIIa; NovoSeven(R), Novo Nordisk, Bagsvaerd, Denmark) has been used for many years in the successful management of bleeding episodes in patients with hemophilia and inhibitors...
  28. pmc The role of tissue factor and factor VIIa in hemostasis
    Nigel Mackman
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, NC 27599 7035, USA
    Anesth Analg 108:1447-52. 2009
    ..However, the mechanism by which recombinant FVIIa restores hemostasis has not been clearly defined. In conclusion, the TF:FVIIa complex is essential for hemostasis and recombinant FVIIa is an effective hemostatic drug...
  29. ncbi Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy
    Lennox Jeffers
    Center for Liver Disease, University of Miami School of Medicine, Miami, Florida 33125, USA
    Gastroenterology 123:118-26. 2002
    ....
  30. ncbi Kinetic modeling sheds light on the mode of action of recombinant factor VIIa on thrombin generation
    Alexander Y Mitrophanov
    DoD Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, US Army Medical Research and Materiel Command, ATTN MCMR TT, 504 Scott Street, Ft Detrick, MD 21702, USA
    Thromb Res 128:381-90. 2011
    ..To elucidate the inherent ability of rFVIIa to modulate thrombin production, it is necessary to identify rFVIIa-induced effects that are compatible with the available biochemical knowledge about thrombin generation mechanisms...
  31. pmc Structure of human factor VIIa and its implications for the triggering of blood coagulation
    A C Pike
    Structural Biology Laboratory, Chemistry Department, University of York, York YO10 5DD, United Kingdom
    Proc Natl Acad Sci U S A 96:8925-30. 1999
    b>Factor VIIa (EC 3.4.21.21) is a trypsin-like serine protease that plays a key role in the blood coagulation cascade. On injury, factor VIIa forms a complex with its allosteric regulator, tissue factor, and initiates blood clotting...
  32. ncbi Recombinant factor VIIa: its background, development and clinical use
    Ulla Hedner
    University of Lund, Sweden
    Curr Opin Hematol 14:225-9. 2007
    ..For the first time it was shown that pharmacological doses of FVIIa induced hemostasis...
  33. ncbi First 20 years with recombinant FVIIa (NovoSeven)
    U Hedner
    Department of Medicine, University of Lund, Lund, Sweden
    Haemophilia 17:e172-82. 2011
    ..By exploiting this mechanism of action, rFVIIa may also be effective in situations other than haemophilia, characterized by an impaired thrombin generation...
  34. ncbi Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial
    Barton Sachs
    Texas Back Institute Clinical Research Organization, Plano, TX, USA
    Spine (Phila Pa 1976) 32:2285-93. 2007
    ..Randomized, placebo-controlled, double-blind, multicenter, Phase IIa study...
  35. ncbi Back to the future: a recent history of haemophilia treatment
    P M Mannucci
    Department of Medicine and Medical Specialties, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, University of Milan and IRCCS Maggiore Hospital, Milan, Italy
    Haemophilia 14:10-8. 2008
    ....
  36. ncbi Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation
    B Sørensen
    Center for Haemophilia and Thrombosis, Department of Clinical Immunology, Aarhus University Hospital, Skejby, Denmark
    J Thromb Haemost 1:551-8. 2003
    ..Preliminary studies in patients substituted with recombinant factor VIIa demonstrated a marked change in the coagulation profile, in which the MaxVel and t,MaxVel shifted towards ..
  37. ncbi Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease
    N S Key
    Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 91:4216-23. 1998
    ..Because TF is the principal cellular ligand for FVIIa, it is possible that increased binding to TF accounts for the diminished plasma FVIIa levels...
  38. pmc Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects
    Evert de Jonge
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, The Netherlands
    Clin Diagn Lab Immunol 10:495-7. 2003
    ..we report that the activation of coagulation in healthy human subjects by the administration of recombinant factor VIIa also elicits a small but significant increase in the concentrations of interleukin 6 (IL-6) and IL-8 in plasma...
  39. ncbi Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma
    Uri Martinowitz
    National Hemophilia Center, Tel Hashomer, Israel
    Can J Anaesth 49:S15-20. 2002
    ..It is approved for use in hemophilia patients, however, its use in trauma is still controversial due to the theoretical risk of thromboembolic complications...
  40. pmc Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
    Sandro B Rizoli
    Department of Surgery and Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, M4N 3M5 Canada
    Crit Care 10:R178. 2006
    We conducted a post-hoc analysis on the effect of recombinant factor VIIa (rFVIIa) on coagulopathic patients from two randomized, placebo-controlled, double-blind trials of rFVIIa as an adjunctive therapy for bleeding in patients with ..
  41. ncbi Herpes simplex virus type 1-encoded glycoprotein C enhances coagulation factor VIIa activity on the virus
    Michael R Sutherland
    Canadian Blood Services, Research and Development Department, Canada
    Thromb Haemost 92:947-55. 2004
    Tissue factor (TF) is the blood coagulation initiator, whose cofactor function is required for physiological factor VIIa (FVIIa)-mediated activation of factor X (FX) to FXa...
  42. ncbi Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors
    Ashish V Joshi
    Novo Nordisk Inc, Princeton, NJ, USA
    Curr Med Res Opin 22:23-31. 2006
    ....
  43. ncbi Factor viia for alveolar hemorrhage in microscopic polyangiitis
    Alan D Betensley
    Am J Respir Crit Care Med 166:1291-2. 2002
  44. ncbi Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor
    Karin Carlsson
    IFM Department of Chemistry, Linkoping University, Linkoping, Sweden
    Eur J Biochem 270:2576-82. 2003
    Blood coagulation is triggered by the formation of a complex between factor VIIa (FVIIa) and its cofactor, tissue factor (TF)...
  45. ncbi Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants
    Kellie A Vavra
    Pharmacy Department, Kaiser Permanente Colorado, Aurora, USA
    Ann Pharmacother 44:718-26. 2010
    To evaluate the use of recombinant factor VIIa (rFVIIa) to reverse major bleeding from newer parenteral anticoagulant therapy.
  46. ncbi The use of recombinant factor VIIa in the treatment of bleeding disorders
    Harold R Roberts
    Division of Hematology Oncology, Department of Medicine and The Carolina Cardiovascular Biology Center, 932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 7035, USA
    Blood 104:3858-64. 2004
    Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in hemophilic patients with inhibitors to factors VIII and IX...
  47. ncbi Treatment with anti-factor VIIa in acute pancreatitis in rats: blocking both coagulation and inflammation?
    Ellen Andersson
    Department of Surgery, Lund University Hospital, Lund, Sweden
    Scand J Gastroenterol 42:765-70. 2007
    ..Several inhibitors of the coagulation cascade, including active-site-inactivated factor VIIa, have shown anti-inflammatory properties in other inflammatory models than acute pancreatitis...
  48. ncbi Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry
    H Chambost
    Paediatric Haematology Department, APHM, Children s Hospital La Timone, Marseille, France INSERM, UMR 1062, Aix Marseille University, Marseille, France
    Haemophilia 19:571-7. 2013
    The ONE Registry (OR) was an international prospective observational study of on-demand recombinant factor VIIa (rFVIIa) treatment for mild to moderate bleeds in haemophilia A/B patients with inhibitors...
  49. ncbi Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats
    B Lauritzen
    Research and Development, Novo Nordisk A S, Måløv, Denmark
    J Thromb Haemost 6:804-11. 2008
    ..Heparin can readily be antagonized with protamine, but this is less effective against LMWH...
  50. ncbi Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders
    Ana Maria Galán
    Hematherapy and Hemostasis Service, Hospital Clinic, Faculty of Medicine, IDIBAPS, Barcelona, Spain
    Transfusion 43:885-92. 2003
    ....
  51. ncbi Use of recombinant factor VIIa in inherited and acquired von Willebrand disease
    Christoph Sucker
    Department of Hemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Dusseldorf, Germany
    Clin Appl Thromb Hemost 15:27-31. 2009
    Recombinant factor VIIa (rFVIIa) is increasingly used outside the labeled indications for the treatment of life-threatening bleeding episodes after failure of respective standard therapy...
  52. ncbi Current insights on the risk of thrombogenicity with off-label use of rFVlla
    Nigel Key
    Division of Hematology, University of North Carolina, Chapel Hill, NC, USA
    Clin Adv Hematol Oncol 4:34-5. 2006
  53. ncbi The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis
    Brian V Norledge
    The Scripps Research Institute, La Jolla, California 92037, USA
    Proteins 53:640-8. 2003
    Factor X is activated to factor Xa (fXa) in the extrinsic coagulation pathway by the tissue factor (TF)/factor VIIa (fVIIa) complex...
  54. pmc Factor VII mutant V154G models a zymogen-like form of factor VIIa
    Raffaella Toso
    Department of Biochemistry and Molecular Biology, University of Ferrara, Via Luigi Borsari, 46 Ferrara 44100, Italy
    Biochem J 369:563-71. 2003
    ....
  55. ncbi Seminal factor VII and factor VIIa: supporting evidence for the presence of an active tissue factor-dependent coagulation pathway in human semen
    Bashir A Lwaleed
    Department of Urology, Southampton University Hospitals NHS Trust, Southampton, UK
    Int J Androl 30:543-9. 2007
    ..This finding reinforces the concept of an active clotting system in human semen, by establishing the missing link in the activation of a TF-dependent pathway...
  56. ncbi Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest
    Roman M Sniecinski
    Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Cardiothorac Vasc Anesth 24:959-63. 2010
    ..This study was undertaken to determine what, if any, the impact of changing antifibrinolytic agents (from aprotinin to tranexamic acid) for deep hypothermic circulatory arrest cases would have on blood bank resource utilization...
  57. ncbi The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0
    E Erhardtsen
    Novo Nordisk A S, Copenhagen, Denmark
    Blood Coagul Fibrinolysis 9:741-8. 1998
    ..coagulation factors, decreases during oral anticoagulant therapy and the administration of recombinant factor VIIa normalizes the prolonged prothrombin time in warfarin-treated rats...
  58. pmc Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients
    H Agersø
    Pharmacology, Biopharmaceuticals Research Unit, Novo Nordisk A S, Maaloev, Denmark
    J Thromb Haemost 9:333-8. 2011
    ..The objective of the present study was to evaluate the pharmacokinetics and the clearance pathways of rFVIIa after intravenous administration to hemophilia patients...
  59. ncbi Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX
    H Ekert
    Haemophilia Treatment Centre, Royal Children s Hospital, Flemington Road, Parkville, Victoria, Australia
    Haemophilia 7:279-85. 2001
    ..Quality-of-life improvements were observed in several important areas as perceived by both patients and their families, at an incremental cost per QALY of A$51 533...
  60. ncbi Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain. A fluorescence resonance energy transfer study
    C D McCallum
    Department of Medical Biochemistry and Genetics, Texas A and M University, College Station, Texas 77843, USA
    J Biol Chem 272:30160-6. 1997
    Coagulation factor VIIa (fVIIa), a soluble serine protease, exhibits full proteolytic activity only when bound to its cofactor, tissue factor (TF)...
  61. ncbi Factor VIIa-tissue factor: functional importance of protein-membrane interactions
    J H Morrissey
    Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA
    Thromb Haemost 78:112-6. 1997
    The first enzyme in the blood clotting cascade consists of two distinct protein subunits: a catalytic subunit (factor VIIa; FVIIa) and an essential regulatory subunit (tissue factor; TF)...
  62. pmc Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity
    E Persson
    Vascular Biochemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    Proc Natl Acad Sci U S A 98:13583-8. 2001
    ..The FVIIa analogues promise to offer a more efficacious treatment of bleeding episodes especially in hemophiliacs with inhibitory antibodies precluding conventional replacement therapy...
  63. pmc Relationships of plasma factor VIIa-antithrombin complexes to manifest and future cardiovascular disease
    Angela Silveira
    Cardiovascular Genetics Group, Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Thromb Res 130:221-5. 2012
    ..VIIa also circulates in inactive form, in complex with antithrombin (VIIaAT) formed when VIIa is bound to tissue factor (TF). This study evaluated VIIaAT in relation to cardiovascular disease (CVD)...
  64. ncbi An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa
    M S Hertzberg
    Department of Haematology, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia
    Blood 94:156-63. 1999
    ..Recombinant factor IXR94S was activated by factor XIa/calcium with an approximately 50-fold reduced rate and by factor VIIa/tissue factor/phospholipid/calcium with an approximately 20-fold reduced rate compared with wild-type factor IX...
  65. ncbi Active site-inactivated factor VIIa inhibits nuclear factor kappa B activation in intestinal ischemia and reperfusion
    Maria M Stollenwerk
    Faculty of Health and Society, Malmo University, Malmo, Sweden
    J Surg Res 178:692-9. 2012
    ..Intestinal I/R injury initiates the extrinsic tissue factor or factor VIIa-dependent pathway of coagulation, also of importance in multiple organ dysfunction syndrome...
  66. ncbi New direct oral anticoagulants--current therapeutic options and treatment recommendations for bleeding complications
    Wolfgang Miesbach
    Medical Clinic III, Institute of Transfusion Medicine, University Hospital, Frankfurt Main, Germany
    Thromb Haemost 108:625-32. 2012
    ..This review summarises potential bleeding management options and available data on the new DOAs...
  67. pmc Factor VIIa binding to endothelial cell protein C receptor: differences between mouse and human systems
    Prosenjit Sen
    Center for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, Texas 75708, USA
    Thromb Haemost 107:951-61. 2012
    ..Our data suggest that one should consider the use of human FVIIa in mouse models to investigate the significance of FVIIa and EPCR interaction...
  68. ncbi Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography, and mass spectrometry
    N K Klausen
    Department of Protein Chemistry Ge, Novo Nordisk A S, Gentofte, Denmark
    Mol Biotechnol 9:195-204. 1998
    The two asparagine-linked glycosylation sites of recombinant coagulation factor VIIa have been characterized by glycosidase digestions, size-exclusion chromatography (SEC), and mass spectrometry (MS)...
  69. ncbi Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood
    Daniel Dirkmann
    Klinik für Anästhesiologie und Intensivmedizin, Universität Duisburg Essen and Universitätsklinikum Essen, Essen, Germany
    Anesth Analg 114:1182-8. 2012
    ..We tested the hypotheses that FXIII concentrate, prothrombin complex concentrate (PCC), recombinant factor VIIa (rFVIIa), and tranexamic acid (TA) inhibit fibrinolysis to different degrees, and that platelets contribute to ..
  70. pmc Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement
    Egon Persson
    Haemostasis Biochemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    Biochem J 379:497-503. 2004
    Coagulation Factor VIIa (FVIIa) lacks the ability to spontaneously complete the conversion to a fully active enzyme after specific cleavage of an internal peptide bond (Arg152-Ile153) in the zymogen...
  71. ncbi The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. A fluorescence energy transfer study
    C D McCallum
    Department of Medical Biochemistry and Genetics, Texas A and M University Health Science Center, College Station, Texas 77843 1114, USA
    J Biol Chem 271:28168-75. 1996
    The topography of membrane-bound blood coagulation factor VIIa (fVIIa) was examined by positioning a fluorescein dye in the active site of fVIIa via a tripeptide tether to yield fluorescein-D-phenylalanyl-L-prolyl-L-arginyl-fVIIa (Fl-FPR-..
  72. pmc Redistribution and hemostatic action of recombinant activated factor VII associated with platelets
    Irene Lopez-Vilchez
    Hemotherapy and Hemostasis Service, Hospital Clinic, Biomedical Diagnostics Center CDB, Institute of Biomedical Research August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Pathol 178:2938-48. 2011
    ..Redistribution of rFVIIa into platelets may explain the prolonged prophylactic effectiveness of rFVIIa in hemophilia...
  73. ncbi Dysinosins B-D, inhibitors of factor VIIa and thrombin from the Australian sponge Lamellodysidea chlorea
    Anthony R Carroll
    Natural Product Discovery, Eskitis Institute, Griffith University, Brisbane, Queensland, Australia 4111
    J Nat Prod 67:1291-4. 2004
    ..These compounds are inhibitors of the blood coagulation cascade serine proteases factor VIIa and thrombin...
  74. ncbi Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol
    P Girard
    Clinical Pharmacology Unit, EA 643 University Claude Bernard, Hopital Cardiologique, Lyon, France
    Thromb Haemost 80:109-13. 1998
    ..The dose producing 50% of the maximum drop of INR was estimated to be 2.2 microg/kg. The model will be used to better define the dosage regimen for future clinical developments...
  75. ncbi Recombinant factor VIIa: a useful tool for life-threatening colonic bleeding. Report of a case
    J G Mitchell
    Department of Colorectal Surgery, Queens Medical Centre, Nottingham, United Kingdom
    Dis Colon Rectum 50:2238-40. 2007
  76. ncbi A clinical review of bleeding dilemmas in trauma
    David B Hoyt
    Department of Surgery, University of California, San Diego, USA
    Semin Hematol 41:40-3. 2004
    ..This paper reviews recent developments and controversies in trauma care, and, in particular, the potential role of procoagulant therapy using recombinant factor VIIa in the prevention of mortality due to bleeding.
  77. ncbi Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders
    Katherine F Croom
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 22:121-36. 2008
    Recombinant factor VIIa (NovoSeven; also known as recombinant activated factor VII or eptacog alfa) is structurally similar to human plasma-derived coagulation factor VIIa, but is manufactured using DNA biotechnology...
  78. ncbi Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count
    T Lisman
    Thrombosis and Hemostasis Laboratory, Department of Hematology, University Medical Center, Utrecht, The Netherlands
    J Thromb Haemost 3:742-51. 2005
    Recombinant factor VIIa (rFVIIa), which was developed for treatment of inhibitor-complicated hemophilia, appears suitable as prohemostatic agent in other clinical disorders including patients with thrombocytopenia...
  79. ncbi Successful treatment of severe gastrointestinal bleeding secondary to Crohn disease with recombinant factor VIIa
    Eva Girona
    Gastroenterology Section, Critical Care Unit, Hospital General Universitario de Elche, Spain
    South Med J 100:601-4. 2007
    ..In this case, the use of recombinant activated factor VIIa controlled the massive gastrointestinal bleeding secondary to Crohn disease and without clinically significant ..
  80. ncbi The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
    Maureane Hoffman
    Dis Mon 49:14-21. 2003
    ..We have previously proposed a platelet-dependent mechanism of action for high-dose factor VIIa (FVIIa; Novoseven, Novo Nordisk, Copenhagen, Denmark)...
  81. ncbi Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa
    K Hicks
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 30:975-8. 2002
    ..The syndrome is associated with a high mortality rate; and current treatment options are limited. Recombinant factor VIIa (rFVIIa, Novoseven) has recently been approved for the treatment of bleeding in patients with hemophilia A/B ..
  82. ncbi The use of recombinant factor VIIa in severe postpartum hemorrhage
    Shmuel Segal
    Barzilai Medical Center, Ashkelon, Israel
    Acta Obstet Gynecol Scand 83:771-2. 2004
  83. ncbi Acquired hemophilia A: clinical features, surgery and treatment of 34 cases, and experience of using recombinant factor VIIa
    Manijeh Lak
    Hematology Department, Hemophilia Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
    Clin Appl Thromb Hemost 16:294-300. 2010
    ..4%), 5 partial efficient treatment (14.7%) and two treatments inefficient (5.9%). Elimination therapy using steroid alone or with combination can terminate complete remission in most cases...
  84. ncbi Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII
    Stephan Malherbe
    Department of Anesthesiology and Pain Medicine, University of Alberta, Edmonton, Canada
    Anesthesiology 100:443-5. 2004
  85. ncbi Use of recombinant factor VIIa in inherited platelet disorders
    Mohamed Kaleelrahman
    Br J Haematol 125:95-6. 2004
  86. ncbi Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial
    Raj K Narayan
    Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA
    Neurosurgery 62:776-86; discussion 786-8. 2008
    ..Recombinant factor VIIa (rFVIIa) is a hemostatic agent that has been shown to limit hemorrhage expansion and which, therefore, could ..
  87. ncbi Caesarean section for placenta praevia complicated by postpartum haemorrhage managed successfully with recombinant activated human coagulation Factor VIIa
    M Gidiri
    Department of Obstetrics and Gynaecology, Hull and East Yorkshire Women and Children s Hospital, Hull, UK
    J Obstet Gynaecol 24:925-6. 2004
  88. ncbi Tissue Factor-Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells
    G Demetz
    Deutsches Herzzentrum und 1 Medizinische Klinik, Technische Universitat Munchen, Lazarettstr 36, 80636 Munich, Germany
    Atherosclerosis 212:466-71. 2010
    Within atherosclerotic lesions Tissue Factor (TF)-Factor VIIa (FVIIa) not only contributes to thrombotic events but also alters vascular remodeling through enhancement of migration...
  89. ncbi Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII
    Walter H Dzik
    Blood Tranfusion Service, Massachusetts General Hospital, Boston, 02114, USA
    J Intensive Care Med 21:54-9. 2006
  90. ncbi Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-κB signaling pathways
    Ying Wu
    Department of Internal Medicine, Affiliated Hospital of Jiangsu University, Jiangsu, PR China
    Cancer Invest 31:7-16. 2013
    ..The effects of FVIIa were TF-dependent and involving PAR2/MAPKs/NF-κB signal transduction pathways. Our study suggests that the links among PAR2/MAPKs/NF-κB may be blocked for effective treatments of colorectal cancers...
  91. ncbi Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety
    M Von Depka
    Werlhof Institute for Haemostasis and Thrombosis, Karl Wiechert Allee, Hannover, Germany
    Haemophilia 11:18-23. 2005
    ..Recombinant FVIIa has demonstrated excellent efficacy and safety, even in patients refractory to other therapies...
  92. ncbi Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion
    Leonie J Siegel
    Department of Anesthesiology, Mannheim University Clinic, Germany
    Anesthesiology 100:441-3. 2004
  93. pmc Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients
    Bartolomeu Nascimento
    Tory Regional Trauma Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canada
    Clinics (Sao Paulo) 66:101-6. 2011
    To determine whether recombinant factor VIIa (rFVIIa) is associated with increased survival and/or thromboembolic complications.
  94. ncbi Tissue factor enhances protease-activated receptor-2-mediated factor VIIa cell proliferative properties
    L Fan
    Center de Recherche, Hopital Sainte Justine, Université de Montréal Montréal, Quebec, Canada
    J Thromb Haemost 3:1056-63. 2005
    ..We speculate that FVIIa-TF-PAR-2 inhibitors may be effective in suppressing cell proliferation...
  95. ncbi Successful treatment of severe retro-peritoneal bleeding with recombinant factor VIIa in women with placenta percreta invading into the left broad ligament: unusual repeated ante-partum intra-abdominal bleeding
    Muhieddine Seoud
    Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Beirut, Lebanon
    J Obstet Gynaecol Res 36:183-6. 2010
    ..bleedings in a woman with placenta percreta invading into the left broad ligament, in whom recombinant factor VIIa was effective for controlling severe retro-peritoneal bleeding...
  96. ncbi Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial
    Stephan A Mayer
    Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Neurocrit Care 4:206-14. 2006
    ..We conducted this trial to evaluate the safety of activated recombinant factor VII (rFVIIa; NovoSeven) for preventing early hematoma growth in acute ICH...
  97. ncbi A novel use of recombinant factor VIIa in HELLP syndrome associated with spontaneous hepatic rupture and abdominal compartment syndrome
    Benjamin W Dart
    Department of Surgery, Division of Surgical Critical Care, University of Tennessee College of Medicine, Chattanooga Unit, Chattanooga, Tennessee 37403, USA
    J Trauma 57:171-4. 2004
  98. ncbi Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study
    J Spira
    Omri Laboratories Ltd, Nes Ziona, Israel
    Haemophilia 16:910-8. 2010
    Recombinant activated factor VIIa (FVIIa) is a bypassing agent used to treat bleeding episodes in haemophilia patients with inhibitors to factor VIII (FVIII) and factor IX...
  99. ncbi Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa
    R M Sugg
    Department of Neurology, The University of Houston Medical School, Houston, TX 77030, USA
    Neurology 67:1053-5. 2006
    We report myocardial injury in 20 recombinant factor VIIa (rFVIIa) treated and 110 nontreated patients with intracerebral hemorrhage. Patients were treated or received standard medical management...
  100. ncbi On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation
    Grigoris T Gerotziafas
    Department of Haematology, Theagenion Cancer Hospital, 2 A Simeonidi Street, 54161 Thessaloniki, Greece
    Br J Haematol 117:705-8. 2002
    ..These data indicate that rFVIIa accelerated thrombin generation without significant increase of generated thrombin...
  101. ncbi Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports
    Barbara L Leighton
    Washington University in Saint Louis School of Medicine, St Louis, Missouri 63110, USA
    Anesthesiology 115:1201-8. 2011
    ..Recombinant factor VIIa (rVIIa) has been used to treat hemorrhage in AFE patients even though rVIIa can combine with circulating tissue ..

Research Grants62

  1. Dual Direct Inhibitors of Thrombin and Factor Xa
    UMESH RAMANLAL DESAI; Fiscal Year: 2012
    ..4) In contrast, they inhibit factor IXa and factor VIIa with IC50 values 60-170-fold and >840-fold higher, respectively suggesting high selectivity for thrombin and ..
  2. Targeted Delivery of a Novel Synthetic Curcumin Analog, EF24 to Glioblastoma and
    MAMORU NONE SHOJI; Fiscal Year: 2012
    ..have developed is EF24, a synthetic curcumin analog, which will be linked to enzymatically inactive coagulation factor VIIa (fVIIa), the high affinity ligand for TF that has exquisite specificity...
  3. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2012
    ..role in other key proteolytic reactions involved in blood coagulation? Factor IXa with its cofactor VIIIa and factor VIIa with its cofactor tissue factor activate factor X to Xa...
  4. TFPI ALPHA AND TFPI BETA
    George J Broze; Fiscal Year: 2013
    ..by applicant): Tissue factor pathway inhibitor (TFPI) produces factor Xa (FXa)-dependent feedback inhibition of factor VIIa/tissue factor (FVIIa/TF)-induced coagulation. In humans, TFPI is expressed as two isoforms...
  5. Factor VIIa Interaction with Endothelial Cell Protein C Receptor
    VIJAYA MOHAN RAO LELLA; Fiscal Year: 2013
    ..Recently, we have shown that factor VIIa (FVIIa) binds specifically to endothelial cell protein C receptor (EPCR) on endothelial cells...
  6. Expansion of intracranial hemorrhage by tPA after traumatic brain injury
    ABD ALROOF HIGAZI; Fiscal Year: 2013
    ..tranexamic acid (TA) and may help explain the increased mortality that follows use of recombinant factor VIIa (rVIIa)...
  7. Association of tissue factor pathway inhibitor with endothelium
    Alan E Mast; Fiscal Year: 2012
    ..Inhibitor (TFPI) is an endothelial associated anticoagulant protein that directly inhibits the Tissue Factor-factor VIIa (TF-fVIIa) catalytic complex preventing intravascular thrombosis, disseminated intravascular coagulation, tumor ..
  8. MOLECULAR INTERACTIONS OF BLOOD COAGULATION FACTOR XA
    Katherine High; Fiscal Year: 1999
    Blood coagulation Factor X occupies a central role in the clotting cascade. It can be activated by either Factor VIIa-tissue factor (extrinsic tenase) or by Factor IXa-VIIIa-phospholipid (intrinsic tenase)...
  9. Structure and Function of Protein-Membrane Interactions in Blood Clotting
    Chad M Rienstra; Fiscal Year: 2013
    ..The primary focus of our studies is the membrane-bound complex of tissue factor and factor VIIa, the two-subunit enzyme responsible for triggering blood clotting in health and disease...
  10. AUTOIMMUNE MECHANISMS OF THROMBOSIS
    Robert Roubey; Fiscal Year: 2004
    ..autoantibodies and autoantibodies to tissue factor pathway inhibitor (TFPI), a critical inhibitor of both factor VIIa/TF and factor Xa...
  11. The Role of Tissue Factor-Factor VIIa-PAR2 Signaling in Breast Tumor Progression
    TROY MCEACHRON; Fiscal Year: 2010
    ..Increased understanding of the metastatic disease process will enable the scientific and medical communities to make advances in therapeutics and treatment strategies. ..
  12. Functional Cooperation of Tissue Factor and Integrins
    Wolfram Ruf; Fiscal Year: 2013
    ..extrinsic coagulation pathway, is upregulated in cancer cells and the complex of TF with its ligand coagulation factor VIIa (FVIIa) contributes to cancer- associated thrombosis and activation of the host hemostatic system in metastasis...
  13. ROLE OF METAL IONS IN THE FUNCTION OF HUMAN FACTOR IX
    Howard Liebman; Fiscal Year: 1992
    ..include studies of the activation of the mutant and partially carboxylated Factor lX proteins by Factor XIa and Factor VIIa-Tissue Factor, enzymatic activity of activated mutant and partially carboxylated Factor lX proteins and studies ..
  14. Induction of Tissue Factor by Patient Sera in HUS
    Eric Grabowski; Fiscal Year: 2007
    ..an antibody directed against activated factor X, recombinant-activated protein C, and active site-inhibited r-factor VIIa. A confirmation that shiga toxin and cytokines present in patient sera augment the TF pathway in our model ..
  15. Molecular Recognition in Factor VIIa Induced Coagulation
    S Bajaj; Fiscal Year: 2005
    This application is based upon the conviction that activation of factor X by the tissue factor/factor VIIa (TF/VIIa) complex represents a key step in the initiation of coagulation by the extrinsic pathway...
  16. MOLECULAR BIOLOGY AND PHYSIOLOGY OF HUMAN FACTOR VII
    Steven Idell; Fiscal Year: 1992
    ..Factor VII is the first zymogen or, in its activated form, factor VIIa is the first serine protease which in association with tissue factor and calcium form the extrinsic pathway ..
  17. INHIBITORS OF THE EXTRINSIC BLOOD COAGULATION PATHWAY
    TERENCE BRUNCK; Fiscal Year: 1991
    ..Synthetic peptides will mimic unique surface accessible regions of Factor VIIa, as determined by sequence and structure analysis...
  18. BLOOD COAGULATION HOMESTASIS: REGULATION OF TFPI
    Alan Schwartz; Fiscal Year: 2003
    ..inhibitor of coagulation is tissue factor pathway inhibitor (TFPI), which produces feedback inhibition of the factor VIIa/tissue factor complex and directly binds and inhibits factor Xa...
  19. FACTOR X ACTIVATION BY THE EXTRINSIC PATHWAY
    Sriram Krishnaswamy; Fiscal Year: 2006
    ..The enzyme complex (extrinsic Xase) that catalyses this reaction is composed of the serine proteinase, factor VIIa, and the integral membrane protein, tissue factor, that associate tightly on a cellular or phospholipid surface ..
  20. Fluorogenic Assays for Factor Vlla and Tissue Factor
    RICHARD JENNY; Fiscal Year: 2006
    b>Factor VIIa and tissue factor (TF) are essential proteins for the initiation of blood coagulation. Blood coagulation is initiated when cryptic TF becomes exposed on the surface of vascular cells where it can bind circulating factor VIla...
  21. NEW THERAPIES FOR HEMOPHILIA
    Nigel Key; Fiscal Year: 2004
    ..a multi- disciplinary approach to this problem, concentrating on bio-engineered clotting factors (mutants of factor VIIa with enhanced pro-coagulant activity, and human-porcine factor VIII hybrid molecules with reduced ..
  22. ENHANCED VITAMIN K DEPENDENT PROTEINS
    Gary Nelsestuen; Fiscal Year: 2002
    ..impact of membrane affinity (specific aim 1) on the enzyme activity of the activated forms of these proteins (factor VIIa and activated protein C, APC), including the impact of cofactor proteins, membrane content, and other ..
  23. TISSUE FACTOR IN BLOOD COAGULATION
    Yale Nemerson; Fiscal Year: 2002
    ..We also are interested in the detailed structure of tissue factor in complex with the enzyme, factor VIIa and the next protein involved in the coagulation scheme, factor X...
  24. SELECTIVE CAPTURE AND QUANTITATION OF SERINE PROTEASES
    RICHARD JENNY; Fiscal Year: 1991
    ..2) To expand and optimize CASSIA technology for the assay of additional serine proteases including thrombin Factor VIIa, Factor IXa, Factor Xa, and activated protein C; and 3) To evaluate the diagnostic potential of each assay ..
  25. SATURATION MUTAGENESIS OF ZEBRAFISH COAGULATION PATHWAY
    Pudur Jagadeeswaran; Fiscal Year: 2003
    ..blood coagulation through the extrinsic pathway is a threshold-mediated event influenced by relative levels of factor VIIa, tissue factor and TFPI activity...
  26. OPTIMIZATION OF AN EFFICACIOUS TUMOR VASCULAR THROMBOGEN
    L Houston; Fiscal Year: 1999
    ..ii) incorporate modifications to the structure human tissue factor (TF), which acts as a cofactor for factor VIIA, that have been shown to increase the safety and decrease the toxicity of TF and (iii) use structural elements ..
  27. THROMBOSIS: ETIOLOGY, RISK FACTORS AND TREATMENT
    RODGER MCEVER; Fiscal Year: 2005
    ..and signaling functions of the endothelial protein C receptor, the membrane requirements of the tissue factor/factor VIIa complex, and the use of gene-targeted mice to study the functions of vascular adhesion and signaling molecules ..
  28. NOVEL INHIBITORS OF COAGULATION PROTEASES
    SUSAN TAMURA; Fiscal Year: 1991
    ..g. Tissue Factor:Factor VIIa (TF:VIIa), Factor Xa, thrombin and kallikrein...
  29. INHIBITION OF TISSUE FACTOR MEDIATED ANGIOGENESIS
    Mamoru Shoji; Fiscal Year: 2001
    ..This will be accomplished by coupling the agent to an inhibitor of coagulation factor VIIa, which possesses five times higher affinity for TF than VIIa...
  30. SERPIN-PROTEASE REACTION, HYDRATION AND GEOMETRY CHANGES
    Maria McGee; Fiscal Year: 2002
    ..3. Characterization of hydration structure of tissue factor and tissue factor/factor VIIa complexes and its relationship to functional binding interaction...
  31. FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    Guy Young; Fiscal Year: 2007
    ..Pharmacokinetic analyses as well as safety and efficacy determinations will be made which will provide valuable information on this new anticoagulant for pediatric patients. [unreadable] [unreadable]..
  32. Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    Guy Young; Fiscal Year: 2009
    ..More modern therapies are available but have not been systematically tested in children. This study will determine whether one such medication, bivalirudin is a safer and more effective alterative. ..
  33. INITIATION AND REGULATION OF BLOOD COAGULATION
    VIJAYA MOHAN RAO LELLA; Fiscal Year: 2010
    ..abstract_text> ..
  34. Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer
    Shaker Mousa; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  35. CELL MEDIATED HEMOSTASIS
    Harold Roberts; Fiscal Year: 2004
    ....
  36. PAR SIGNALING AND PROTECTIVE PATHWAYS IN INFLAMMATION AND SEPSIS
    Wolfram Ruf; Fiscal Year: 2010
    ..3. ..
  37. TARGETING SIGNALING OF THE TISSUE FACTOR PATHWAY
    Wolfram Ruf; Fiscal Year: 2007
    ..abstract_text> ..
  38. Tissue Factor-factor Vlla signaling
    Usha Pendurthi; Fiscal Year: 2010
    ..The proposed studies will provide valuable information in understanding how TF contributes to tumorigenesis. These studies will also provide clues on potential therapeutic targets for prevention of cancer progression. ..
  39. Pathophysiology of anti-B2GPI Antibodies in APS
    ALISA WOLBERG; Fiscal Year: 2008
    ..It is expected that these proposed studies will contribute to a fundamental understanding of pathogenic mechanisms for thrombosis in APS and lead to future investigations addressing therapeutic interventions in APS. ..
  40. Pathophysiology of thiamine-responsive anemia syndrome
    Ellis Neufeld; Fiscal Year: 2006
    ....
  41. 26th Princeton Conference on Cerebrovascular Disease
    James Grotta; Fiscal Year: 2008
    ..All presentations and discussion will be recorded and published. [unreadable] [unreadable] [unreadable]..
  42. Symphony Multiplex Peptide Synthesizer w/ VISION Workstn
    Kenneth Mann; Fiscal Year: 2004
    ..There is currently no preparative HPLC system on the campus of the University of Vermont and this system is badly needed for many investigators. ..
  43. PE BIOSYSTEMS VOYAGER DE MALDI-TOF
    Kenneth Mann; Fiscal Year: 2001
    ..The fulfillment of the specific aims described in detail in the twelve research proposals would be facilitated by the addiction of a Voyager-DE MALDI-TOF ..
  44. FAT MEDIATED INSULIN SECRETION AND DIABETES IN ELDERLY
    Guenther Boden; Fiscal Year: 2003
    ..We hope that this project will help to better understand the mechanisms by which obesity contributes to the development of NIDDM. ..
  45. BIACORE 3000
    PIERRE NEUENSCHWANDER; Fiscal Year: 2003
    ....
  46. VASCULAR BIOLOGY IN CANCER
    Thomas Edgington; Fiscal Year: 2006
    ..Weekly seminars and review of data are conducted by each of the faculty members with their group. M.D., Ph.D. and M.D./Ph.D. candidates are recruited and prepared for an independent investigative career. ..
  47. HUMAN TISSUE FACTOR AND ITS PLASMA INHIBITOR
    George Broze; Fiscal Year: 2001
    ..3) further characterize TFPIK1 gene-disrupted mice which have an isolated deficiency in TFPI-mediated factor VIIa/TF inhibition; 4) produce TFPI null mice and compare their phenotype with that of TFPIK1 mice; and 5) attempt ..
  48. Antithrombotic Gene Therapy
    Pierre Zoldhelyi; Fiscal Year: 2006
    ..We hypothesize that gene transfer of TFPI and PGHS-1 will achieve lasting vasoprotection without hemorrhagic risk. ..
  49. Designing Mechanism-based Anticoagulants
    Umesh Desai; Fiscal Year: 2006
    ..abstract_text> ..
  50. Outcome and Quality of Life after Diabetic Stroke
    Brett Kissela; Fiscal Year: 2007
    ..It is the goal of the Prinicipal Investigator to become an expert in epidemiology and outcomes research and to use clinical research to improve the lives of diabetic patients with stroke. ..
  51. Free Fatty Acids and Hepatic Insulin Resistance
    Guenther Boden; Fiscal Year: 2007
    ..These studies will hopefully provide much needed information relative to important details and mechanisms of FFA induced hepatic insulin resistance. [unreadable] [unreadable]..
  52. Fat Induced Insulin Resistance and Atherosclerosis
    Guenther Boden; Fiscal Year: 2007
    ..We believe that these studies will provide important new information relative to the mechanism by which obesity and FFAs cause IR and ASVD in human subjects. ..
  53. Vascular Biology of Tissue Factor
    Wolfram Ruf; Fiscal Year: 2008
    ..These studies have, and will continue to produce original data and advanced knowledge of the TF driven thrombotic and inflammatory diseases and new routes to reduce the impact of these diseases. ..
  54. Pathophysiologies Involving Hemostasis-related Genes
    Francis Castellino; Fiscal Year: 2008
    ..abstract_text> ..
  55. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2008
    ..The major aim of this project is to elucidate the structure/function relationships of this material with respect to factor V inactivation and to access its potential significance in the pathology of human thrombosis. ..
  56. Structural Mechanisms for the Inhibition of Thrombosis
    JAMES HUNTINGTON; Fiscal Year: 2009
    ....
  57. Pathogenesis of HIV and HCV in Hemophilia: HGDS
    Edward Gomperts; Fiscal Year: 2004
    ..This study will utilize state-of-the-art technology in a well-characterized cohort to expand the current understanding of host and immune factors that influence viral replication and clinical disease progression. ..
  58. EFFECTS OF TF/FVIIa INHIBITION IN CRP TRANSGENIC MICE
    Christopher Arnold; Fiscal Year: 2004
    ..Together, these models will help determine the in vivo anti-inflammatory and antithrombotic properties of BCX-3607, a potential agent for the treatment of acute coronary syndromes. ..
  59. Functional Domains of Coagulation Factor V
    Michael Kalafatis; Fiscal Year: 2007
    ..We have established a system to study phospholipids-driven macromolecular complex formation, which may be a model for the generation of complexes that form extra-and intra-cellularly. ..
  60. Structural Mechanisms of Factor IXa Function
    PIERRE NEUENSCHWANDER; Fiscal Year: 2009
    ..As such, this work will foster the development of novel therapeutics for either coagulopathies or bleeding disorders. ..
  61. TFPI ALPHA AND TFPI BETA
    George Broze; Fiscal Year: 2009
    ..by applicant): Tissue factor pathway inhibitor (TFPI) produces factor Xa (FXa)-dependent feedback inhibition of factor VIIa/tissue factor (FVIIa/TF)-induced coagulation. In humans, TFPI is expressed as two isoforms...